Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

Abstract Background Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have become significant global health concerns. In the present study, we aimed to investigate the effects of saroglitazar, a dual PPARα/γ agonist, fenofibrate, a PPAR-α agonist, and pioglitazone, a...

Full description

Bibliographic Details
Main Authors: Rasoul Akbari, Tahereh Behdarvand, Reza Afarin, Hamid Yaghooti, Mohammad Taha Jalali, Narges Mohammadtaghvaei
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Pharmacology and Toxicology
Subjects:
Saroglitazar
NASH
PPAR- α/γ
TNF- α
TGF-β
MCP-1
Online Access:https://doi.org/10.1186/s40360-021-00524-8

Internet

https://doi.org/10.1186/s40360-021-00524-8

Similar Items